Cosmos Health Inc. - Common Stock (NQ:COSM)

Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target

October 28, 2026

Rating and price target: Outperform rating with a $1.40 price target Implied upside: approximately 493% above the $0.236 closing price on Tuesday, October 27, 2026 Valuation basis: 1.42 times Noble's...

Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway

Performance

52-Week Range 67.6% below 52-week high

0.3079

0.1652W Low 0.9552W High

1 Week 0.7% below 1-week high

0.221W Low 0.311W High

Cosmos Health Inc. - Common Stock (COSM) traded between $0.16 and $0.95 over the past 52 weeks and last traded at $0.31, 67.6% below its 52-week high. Over the past week it ranged between $0.22 and $0.31.

Past 12 Months

+32.5%

-20.3%

+31.0%

-13.8%

-40.2%

-62.0%

1W +$0.08

1M -$0.08

3M +$0.07

6M -$0.05

YTD -$0.21

1Y -$0.50

COSM was -62.0% over the past year, -13.8% over six months, -40.2% year to date, +32.5% in the last week.

12 Months vs Market

COSM

-62.0%

DIA

+8.7%

SPY

+10.8%

QQQ

+9.8%

IWM

+13.4%

Over the past 12 months COSM returned -62.0% versus DIA (Dow) +8.7%, SPY (S&P 500) +10.8%, QQQ (Nasdaq 100) +9.8% and IWM (Russell 2000) +13.4%.

Volume & Liquidity 0.68× 3-mo avg

Today 2,110,064 3-mo avg 3.1M

2.4M

2.6M

3.1M

6.2M

YTD

4.1M

3.5M

COSM most recently traded 2,110,064 shares against a 3-month average daily volume of 3.1M.

More News

October 22, 2026

Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

October 20, 2026

Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days

October 19, 2026

Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription

October 14, 2026

Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days

October 13, 2026

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million

October 07, 2026

Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

October 01, 2026

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue

September 29, 2026

Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

September 28, 2026

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

September 15, 2026

Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market

September 14, 2026

Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units

September 11, 2026

Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market

September 09, 2026

Cosmos Health: A Company Transformed — 2026 Year-to-Date

September 03, 2026

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

August 28, 2026

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

August 24, 2026

Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

August 20, 2026

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

August 19, 2026

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

July 27, 2026

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

July 20, 2026

Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases

July 17, 2026

Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

July 16, 2026

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

July 15, 2026